635% Growth For American Lithium Company After They Fight Back Against China
The USA is fighting an economic war with China over lithium. Until now, we've been losing (with China controlling 80% of lithium production). But this small lithium company could change that with their significant holdings in the hottest area of the US for lithium discoveries.
They've Already Seen 635% Growth In 2021

VLON Insider Trading (Vallon Pharmaceuticals)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $28,780.64
Insider Selling (Last 12 Months): $0.00

Vallon Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Vallon Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vallon Pharmaceuticals Share Price & Price History

Current Price: $5.50
Price Change: Price Increase of +0.19 (3.58%)
As of 11/29/2021 02:03 PM ET

This chart shows the closing price history over time for VLON up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Breaking News Just Announced
This tiny telehealth stock is up over 50% in the past month.
Put it on your watchlist now

Vallon Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/4/2021Leanne M. KellyCFOBuy1,508$4.08$6,152.643,657View SEC Filing Icon  
6/2/2021Leanne M. KellyCFOBuy3,657$4.00$14,628.003,657View SEC Filing Icon  
2/12/2021David Charles BakerCEOBuy1,000$8.00$8,000.00
See Full Table
Insider Buying at Vallon Pharmaceuticals?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Vallon Pharmaceuticals and related companies.

SEC Filings (Institutional Ownership Changes) for Vallon Pharmaceuticals (NASDAQ:VLON)

8.51% of Vallon Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at VLON by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Vallon Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/12/2021Geode Capital Management LLC24,134$0.18M0.0%+84.0%0.354%Search for SEC Filing on Google Icon
11/5/2021Advisor Group Holdings Inc.6,890$50K0.0%+57.4%0.101%Search for SEC Filing on Google Icon
8/17/2021Zeke Capital Advisors LLC30,000$0.16M0.0%N/A0.440%Search for SEC Filing on Google Icon
8/13/2021Altium Capital Management LP161,440$0.88M0.2%-46.2%2.370%Search for SEC Filing on Google Icon
8/13/2021Murchinson Ltd.194,900$1.06M0.4%N/A2.861%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC13,116$71K0.0%N/A0.193%Search for SEC Filing on Google Icon
8/4/2021Envestnet Asset Management Inc.17,513$95K0.0%+48.7%0.257%Search for SEC Filing on Google Icon
5/18/2021Millennium Management LLC28,461$0.13M0.0%N/A0.418%Search for SEC Filing on Google Icon
5/17/2021Ikarian Capital LLC140,000$0.65M0.0%N/A2.055%Search for SEC Filing on Google Icon
5/6/2021Altium Capital Management LP300,000$1.39M0.4%N/A4.405%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
Read More on Vallon Pharmaceuticals

Today's Range

Now: $5.50
Low: $5.15
High: $5.65

50 Day Range

MA: $6.29
Low: $4.02
High: $9.68

52 Week Range

Now: $5.50
Low: $3.61
High: $10.36

Volume

12,813 shs

Average Volume

275,127 shs

Market Capitalization

$37.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Vallon Pharmaceuticals?

Vallon Pharmaceuticals' top insider investors include:
  1. Leanne M Kelly (CFO)
  2. David Charles Baker (CEO)
  3. Joseph E Payne (Director)

Who are the major institutional investors of Vallon Pharmaceuticals?

Vallon Pharmaceuticals' top institutional investors include:
  1. Geode Capital Management LLC — 0.35%
  2. Advisor Group Holdings Inc. — 0.10%

Which major investors are buying Vallon Pharmaceuticals stock?

During the last quarter, VLON stock was bought by institutional investors including:
  1. Geode Capital Management LLC
  2. Advisor Group Holdings Inc.
During the previous year, these company insiders have bought Vallon Pharmaceuticals stock:
  1. Leanne M Kelly (CFO)
  2. David Charles Baker (CEO)
  3. Joseph E Payne (Director)
Could This Seattle Pot Stock SOAR as Legal Weed Market Expands?
Fifteen states plus the District of Columbia now permit the recreational use of cannabis and Congress is on track to decriminalize marijuana possession on the federal level. As a result, the North American cannabis market is expected to TRIPLE in size from $30 billion to $100 billion by the year 2027 – and one Seattle manufacturer is poised to cash in!
Details in Brand-New Special Report!